Increasing timely access to medicines for patients suffering from rare diseases.
One in 12 Canadians, two-thirds of them children, suffer from a rare disease. IMC is committed to advocating for policies that increase timely access to medicines and treatments for patients suffering from rare diseases.
Canada desperately needs a rare disease strategy that’ll enable better patient care and access to treatment for those living with rare diseases.
Ottawa, July 24, 2024 – Innovative Medicines Canada (IMC) is encouraged by the announcement that the federal government and the […]
Further delays risk undermining the health and well-being of the very patients the National Strategy for Drugs for Rare Diseases was intended to assist.
Ottawa, March 22, 2023 – Innovative Medicines Canada (IMC) is encouraged by the federal government’s announcement regarding its intentions for […]
Innovative Medicines Canada provides Health Canada with additional input regarding IMC’s March 2021 consultation submission on drugs for rare diseases.
IMC proposes a value-based, pan-Canadian rare disease strategy, built in collaboration with provinces, patients, clinicians and industry to fill gaps and meet specific needs.
Public plans in Canada cover fewer medicines than in other OECD20 countries and take longer to be approved. For rare-disease medicines, this gap is even larger.
Sorry, no posts were found. Please check again later.
Breaking down and analyzing current events in the healthcare industry for our members, policy influencers and the Canadian public.
Our member companies, which range from early-stage startups to established organizations, are revolutionizing healthcare through the discovery and development of new […]
Informative content to keep you up to date on the most pressing issues facing our industry.
